Literature DB >> 19026700

Interleukin-1RN gene polymorphisms in elderly patients with rheumatic inflammatory chronic conditions: Association of IL-1RN*2/2 genotype with polymyalgia rheumatica.

Lorena Alvarez-Rodriguez1, Eugenio Carrasco-Marin, Marcos Lopez-Hoyos, Cristina Mata, Lorena Fernandez-Prieto, Maria Ruiz-Soto, Jaime Calvo, Vicente Rodriguez-Valverde, Teresa Ruiz, Ricardo Blanco, Alfonso Corrales, Victor Manuel Martinez-Taboada.   

Abstract

The objective of this study was to investigate whether there is an association between IL1RN polymorphism and disease susceptibility for three age-related inflammatory conditions: polymyalgia rheumatica (PMR), giant cell arteritis (GCA), and elderly-onset rheumatoid arthritis (EORA). A tandem-repeat polymorphism within IL1RN intron 2 was analyzed in 139 PMR, 69 GCA, and 156 RA patients (75 with EORA) as well as in 437 healthy subjects, together with the in vitro production of IL-1beta. Our results showed that the IL1RN*2/2 genotype was more frequent in PMR patients compared with controls (p = 0.032, odds ratio = 1.785, 95% confidence interval = 1.047-3.044) and GCA patients (p = 0.008, odds ratio = 4.661, 95% confidence interval = 1.352-16.065). We found no difference in the distribution of genotypes between PMR and EORA or between EORA and controls. However, the frequency of the IL-1RN*2/2 genotype had a tendency to be higher in patients with EORA compared with young onset RA. The presence of IL1RN*1 or IL1RN*2 allele was not associated with severity of the disease in PMR and GCA patients and did not influence the production of IL-1beta. In conclusion, the IL1RN*2 polymorphism in a homozygous state was associated with an increased susceptibility to PMR and may give some clues for a differential therapy with GCA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19026700     DOI: 10.1016/j.humimm.2008.10.011

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  7 in total

Review 1.  Cytokine gene considerations in giant cell arteritis: IL10 promoter polymorphisms and a review of the literature.

Authors:  Lorena Alvarez-Rodriguez; Marcos Lopez-Hoyos; Eugenio Carrasco-Marín; Gaurav Tripathi; Pedro Muñoz Cacho; Cristina Mata; Jaime Calvo-Alen; Maite Garcia-Unzueta; Elena Aurrecoechea; Victor Manuel Martinez-Taboada
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

2.  Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma.

Authors:  Normann Steiner; Georg Göbel; Daniela Michaeler; Anna-Luise Platz; Wolfgang Prokop; Anna Maria Wolf; Dominik Wolf; Christina Duftner; Eberhard Gunsilius
Journal:  Blood Adv       Date:  2021-03-23

Review 3.  Associations between interleukin-1 polymorphisms and susceptibility to vasculitis: a meta-analysis.

Authors:  G G Song; J-H Kim; Y H Lee
Journal:  Z Rheumatol       Date:  2016-05       Impact factor: 1.372

Review 4.  Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-02       Impact factor: 5.346

5.  The risk of polymyalgia rheumatica in older adults with gout: a Medicare claims study.

Authors:  Jasvinder A Singh; John D Cleveland
Journal:  Rheumatol Adv Pract       Date:  2018-06-20

6.  Polymyalgia rheumatica: an autoinflammatory disorder?

Authors:  Alberto Floris; Matteo Piga; Alberto Cauli; Carlo Salvarani; Alessandro Mathieu
Journal:  RMD Open       Date:  2018-06-04

7.  IL-25 exacerbates autoimmune aortitis in IL-1 receptor antagonist-deficient mice.

Authors:  Takamichi Yoshizaki; Satoshi Itoh; Sachiko Yamaguchi; Takafumi Numata; Aya Nambu; Naoyuki Kimura; Hajime Suto; Ko Okumura; Katsuko Sudo; Atsushi Yamaguchi; Susumu Nakae
Journal:  Sci Rep       Date:  2019-11-19       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.